V. Subbiah

The evolving landscape of tissue-agnostic therapies in precision oncology.

Mohamed A. Gouda, V. Subbiah, B. Ryll, 2024, CA: a cancer journal for clinicians.

Impact of tissue-agnostic approvals on management of primary brain tumors.

A. Khosla, Mohamed A. Gouda, Ahmad Ozair, 2024, Trends in cancer.

TRKing sarcomas for precision medicine: Seek, and ye shall find!

V. Subbiah, J. T. Moyers, 2023, Cancer.

Clinical development and management of adverse events associated with FGFR inhibitors

S. Verstovsek, V. Subbiah, 2023, Cell reports. Medicine.

Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors

A. Naing, S. Piha-Paul, B. Stephen, 2024, Cancer medicine.

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

F. Janku, A. Naing, S. Piha-Paul, 2023, Cancer research communications.

Variant of allele frequency: a decision-making tool in precision oncology?

C. Criscitiello, G. Curigliano, E. Crimini, 2023, Trends in cancer.

Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001

A. Drilon, M. Brose, B. Deschler-Baier, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.